News und Analysen

Pflichtmitteilung:

Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher

Lyon, 9 September 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and Beyond Batten Disease Foundation (BBDF), announce receipt of

(Data have been the subject to a limited review by the statutory auditors)

The Board of Directors, at its meeting of September 8, 2021, made up the half-year statutory and consolidated financial

As part of its population health strategy to improve the health of its members and communities, Humana Inc. (NYSE: HUM) today announced a $25 million investment to increase the supply of affordable

Novocure (NASDAQ: NVCR) today announced the United States Food and Drug Administration (FDA) has granted breakthrough designation to the NovoTTF-200T System, a Tumor Treating Fields (TTFields)

Pfizer Inc. (NYSE: PFE) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for CIBINQO^® (abrocitinib), an oral

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908006154/en/

Regulatory News:

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities

Curant Health and Humana Inc. (NYSE: HUM) have teamed up to help achieve better health outcomes for Humana members suffering from Chronic Heart Failure (CHF) and Chronic Obstructive Pulmonary

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn

Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, and 11 leading health systems acquired a minority stake in Exela Holdings, Inc., the holding company of

Regulatory News:

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology, which specializes in the development of novel therapies to restore, treat and prevent

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that on September 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of

Regulatory News:

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer executives at two upcoming healthcare conferences.

Frank D’Amelio, Chief

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced the company’s management team

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including:

• 
  Wells Fargo 2021 Healthcare

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the following healthcare

Agilent Technologies Inc. (NYSE: A) today announced Dr. David R. Liu has been selected to receive a prestigious Agilent Thought Leader Award. A prominent researcher in the field of genome editing

Premier, Inc. (NASDAQ: PINC) today announced it has decreased the size of its Board of Directors from 15 to 11, effective August 31, 2021, to further enhance the company’s governance profile. In

Pflichtmitteilung:

Valbiotis (FR0013254851 – ALVAL, PEA/SME-fähig), ein französisches Forschungs- und Entwicklungsunternehmen, das sich wissenschaftlichen Innovationen zur Prävention und

Newron Pharmaceutical S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral

Regulatory News:

Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a French research and development company committed to scientific innovation for preventing and combating metabolic diseases

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral